购物车
- 全部删除
- 您的购物车当前为空
Anti-RANKL/TNFSF11/CD254 Antibody (8L355) 是一种 Rabbit 抗体,靶向 RANKL/TNFSF11/CD254。Anti-RANKL/TNFSF11/CD254 Antibody (8L355) 可用于 ELISA,ELISA(Det)。
Anti-RANKL/TNFSF11/CD254 Antibody (8L355) 是一种 Rabbit 抗体,靶向 RANKL/TNFSF11/CD254。Anti-RANKL/TNFSF11/CD254 Antibody (8L355) 可用于 ELISA,ELISA(Det)。
产品描述 | Anti-RANKL/TNFSF11/CD254 Antibody (8L355) is a Rabbit antibody targeting RANKL/TNFSF11/CD254. Anti-RANKL/TNFSF11/CD254 Antibody (8L355) can be used in ELISA,ELISA(Det). |
Ig Type | Monoclonal Rabbit IgG |
克隆号 | 8L355 |
交叉反应 | Human |
验证活性 | 1. Anti-TNFSF11 rabbit monoclonal antibody at 1:500 dilution. -Lane A: 293T Membrane lysate. -Lysates/proteins at 30 μg per lane. -Secondary -Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution. -Developed using the Odyssey technique. -Performed under reducing conditions. -Predicted band size:35 kDa. -Observed band size:38 kDa. 2. TNFSF11 was immunoprecipitated using: -Lane A:0.5 mg Raji Whole Cell Lysate -0.5 µL anti-TNFSF11 rabbit monoclonal antibody and 15 μl of 50 % Protein G agarose. -Primary antibody: -Anti-TNFSF11 rabbit monoclonal antibody, at 1:500 dilution. -Secondary antibody: -Dylight 800-labeled antibody to rabbit IgG (H+L), at 1:5000 dilution. -Developed using the odyssey technique. -Performed under reducing conditions. -Predicted band size: 35 kDa. -Observed band size: 40 kDa |
应用 | ELISA,ELISA(Det) |
推荐剂量 | ELISA: 1:25000-1:50000; ELISA(Det): 1:5000-1:50000 |
抗体种类 | Monoclonal |
宿主来源 | Rabbit |
构建方式 | This antibody was obtained from a rabbit immunized with purified, recombinant Human RANKL / OPGL / TNFSF11 / CD254 (rh RANKL / OPGL / TNFSF11 / CD254; TMPY-03364; AAC51762.1;Gly64-Asp245). |
纯化方式 | Protein A |
性状 | Liquid |
缓冲液 | 0.2 μm filtered solution in PBS |
研究背景 | Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
偶联 | Unconjugated |
免疫原 | Recombinant Human RANKL / OPGL / TNFSF11 / CD254 protein (TMPY-03364) |
抗原种属 | Human |
研究领域 | Cancer Drug Targets |
储存方式 | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
运输方式 | Shipping with blue ice. |
评论内容